Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBT Margin (2020 - 2023)

Historic EBT Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 119.24%.

  • Candel Therapeutics' EBT Margin rose 252839900.0% to 119.24% in Q4 2023 from the same period last year, while for Dec 2023 it was 1299.23%, marking a year-over-year increase of 270967400.0%. This contributed to the annual value of 1444.74% for FY2024, which is 1455100.0% down from last year.
  • Latest data reveals that Candel Therapeutics reported EBT Margin of 119.24% as of Q4 2023, which was up 252839900.0% from 1349.48% recorded in Q3 2023.
  • Candel Therapeutics' EBT Margin's 5-year high stood at 1565.02% during Q1 2023, with a 5-year trough of 29551.61% in Q1 2022.
  • In the last 4 years, Candel Therapeutics' EBT Margin had a median value of 17148.39% in 2021 and averaged 15260.68%.
  • As far as peak fluctuations go, Candel Therapeutics' EBT Margin crashed by -172096800bps in 2021, and later soared by 311166400bps in 2023.
  • Candel Therapeutics' EBT Margin (Quarter) stood at 19600.0% in 2020, then dropped by -28bps to 25003.23% in 2021, then decreased by -2bps to 25403.23% in 2022, then skyrocketed by 100bps to 119.24% in 2023.
  • Its EBT Margin stands at 119.24% for Q4 2023, versus 1349.48% for Q3 2023 and 1517.08% for Q2 2023.